Client Result
Orrick Advises Kain Capital on Investment in MY DR NOW
September.01.2022
The investment marks the first time MY DR NOW has received external capital.
Search Results
News
American Lawyer Again Names Josh Rosenkranz “Litigator of the Year” Finalist
August.08.2022
American Lawyer has twice before recognized Josh as Litigator of Year.
News
Life Sciences Highlights for H1 2022
August.01.2022
In the first half of 2022, our teams advised on 80 mergers, acquisitions, VC financings and other transactions in the Life Sciences sector.
Client Result
Orrick Advises Medical Microinstruments on $75 Million Series B Round
July.25.2022
Medical Microinstruments is a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery.
Client Result
Orrick Advises MorphoSys on Equity Participation Transaction with HIBio
July.08.2022
Orrick advised German biopharmaceutical company MorphoSys on its equity participation transaction with biotech company Human Immunology Biosciences
Client Result
Orrick Advises Ipsen on Acquisition of Epizyme
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
Client Result
Orrick Advises Aledade on $123 Million Series E
June.06.2022
Returning investor OMERS Growth Equity led the round, which also included Fidelity Management & Research Company and other current investors.
Client Result
Orrick Advises Kineta on Merger with Yumanity Therapeutics
June.06.2022
Under the definitive agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction.
News
Orrick’s Gregg Griner Named Life Sciences Go-To Lawyer
May.31.2022
Congratulations to Orrick partner Gregg Griner on being recognized as a Go-To Lawyer for Healthcare and Life Sciences by Massachusetts Lawyers Weekly.
News
Japan Team Ranks Tier 1 in Asia IP Rankings 2022 by Asian Legal Business
May.27.2022
Orrick has been selected as one of Japan’s top law firms in the following categories in the "Asia IP Rankings 2022" published by ALB.
Client Result
Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio
May.24.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.
Client Result
Orrick Advises Stripes on Investment in Hello Heart
May.03.2022
Orrick advised Stripes on its investment in digital therapeutics company Hello Heart’s $70 million Series D funding round.